Effect of Plant Sterols Esterified to Fish Oil Fatty Acids on Plasma Lipid Levels
Primary Purpose
Dyslipidemia
Status
Completed
Phase
Phase 4
Locations
Israel
Study Type
Interventional
Intervention
Plant sterols esters
placebo
Sponsored by
About this trial
This is an interventional treatment trial for Dyslipidemia focused on measuring Hypercholesterolemia, Hypertriglyceridemia, Plant sterol, Cholesterol, Fish oil
Eligibility Criteria
Inclusion Criteria:
- Male or female, >18 years old and ≤ 70 years old, capable and willing to give written informed consent.
- Subject must have hyperlipidemia at the screening visit and at the end of the run-in period, defined as: fasting plasma triglycerides > 150 mg/dl and < 500 mg/dl, LDL-cholesterol > 130 mg/dl and < 190 mg/dl.
- Fasting plasma glucose (FPG) levels at the screening visit < 110 mg/dl.
- Female patient who is of reproductive potential agree to use acceptable methods of birth control
- Female patient who is currently receiving hormone replacement therapy continuously 12 weeks before visit 1 (on stable dose) and will agree to do so during the study.
Exclusion Criteria:
- Receiving medications or supplements known to affect lipid metabolism.
- Uncontrolled hypertension or thyroid disease.
- Consume unusual diets - will be determined at the discretion of the investigator.
- Gained or lost more than 3 kg during the run-in period.
- Patient has history of malignancy ≤ 5 years.
- Patients with clinical ischemic CV disease on treatment
- Consume 200 grams fish x 2 a week.
- Gastrointestinal disease or any disease that the investigator feels would compromise the patient safety or limit his/her successful participation to the study.
- Patient has type 1 or type 2 diabetes mellitus.
- Patient has uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins
- Patient has had active peptic ulcer disease within 3 months of visit 1.
- Woman patient is pregnant or breast-feeding or expecting to conceive during the study.
- Patient has a history of hypersensitivity or allergy to fish, fish oil, corn oil or soy.
Sites / Locations
- Sheba medical center
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Plant sterol esters
placebo
Arm Description
plant sterols esterified to fish oil fatty acids
Corn oil
Outcomes
Primary Outcome Measures
LDL Cholesterol
Average of blood test results at -10 and 0 days (before and after run-in period)
LDL-C
Blood test results following 12 weeks of intervention
Secondary Outcome Measures
Triglycerides
Average of blood test results at -10 and 0 weeks (before and after run-in period)
Triglycerides
Blood test results following 12 weeks of intervention
Total Cholesterol
Average of blood test results at -10 and 0 weeks (before and after run-in period)
Total Cholesterol
Blood test results following 12 weeks of intervention
HDL Cholesterol
Average of blood test results at -10 and 0 weeks (before and after run-in period)
HDL-cholestrol
Blood test results following 12 weeks of intervention
CRP
Blood test results on day 0 of High sensitivity C Reactive Protein
CRP
Blood test results following 12 weeks of intervention of High sensetivity C reactive protein
Apolipoprotein B100
Blood test results on day 0
Apolipoprotein B100
Blood test results follwing 12 weeks of intervention
Apolipoprotein A
Blood test on day 0
Apolipoprotein A
Blood test results following 12 weeks of intervention
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00441480
Brief Title
Effect of Plant Sterols Esterified to Fish Oil Fatty Acids on Plasma Lipid Levels
Official Title
Effect of Plant Sterols Esterified to Fish Oil Fatty Acids on Plasma Lipid Levels in Healthy, Hyperlipidemic Subjects
Study Type
Interventional
2. Study Status
Record Verification Date
January 2012
Overall Recruitment Status
Completed
Study Start Date
March 2007 (undefined)
Primary Completion Date
June 2008 (Actual)
Study Completion Date
June 2008 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Enzymotec
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to determine whether plant sterols esterified to fish oil fatty acids in a fish oil matrix improve the lipid profile, predominantly LDL-cholesterol and TG concentrations in healthy hyperlipidemic subjects.
Detailed Description
Phytosterols and omega-3 fatty acids (n-3) are natural food ingredients with potential cardiovascular (CVD) benefits. Phytosterols inhibit dietary cholesterol absorption and biliary cholesterol re-absorption, thereby reducing blood cholesterol levels, while consumption of n-3 is associated with a significant reduction in plasma triglyceride concentrations. Furthermore, n-3 may also beneficially modify a number of other risk factors of CHD, like anti-inflammatory and anti-thrombotic.
The primary objective of this study is to determine whether plant sterols esterified to fish oil fatty acids in a fish oil matrix improve the lipid profile, predominantly LDL-cholesterol and TG concentrations in healthy hyperlipidemic subjects. In addition the supplement efficacy to lower other CVD-related risk factors of healthy will be evaluated.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dyslipidemia
Keywords
Hypercholesterolemia, Hypertriglyceridemia, Plant sterol, Cholesterol, Fish oil
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
91 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Plant sterol esters
Arm Type
Active Comparator
Arm Description
plant sterols esterified to fish oil fatty acids
Arm Title
placebo
Arm Type
Placebo Comparator
Arm Description
Corn oil
Intervention Type
Dietary Supplement
Intervention Name(s)
Plant sterols esters
Other Intervention Name(s)
PS-FO
Intervention Description
1.6g phytosterols and 1.3g omega-3 fatty acids per day
Intervention Type
Dietary Supplement
Intervention Name(s)
placebo
Intervention Description
4 gr of corn oil
Primary Outcome Measure Information:
Title
LDL Cholesterol
Description
Average of blood test results at -10 and 0 days (before and after run-in period)
Time Frame
at baseline
Title
LDL-C
Description
Blood test results following 12 weeks of intervention
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Triglycerides
Description
Average of blood test results at -10 and 0 weeks (before and after run-in period)
Time Frame
at baseline
Title
Triglycerides
Description
Blood test results following 12 weeks of intervention
Time Frame
12 weeks
Title
Total Cholesterol
Description
Average of blood test results at -10 and 0 weeks (before and after run-in period)
Time Frame
at baseline
Title
Total Cholesterol
Description
Blood test results following 12 weeks of intervention
Time Frame
12 weeks
Title
HDL Cholesterol
Description
Average of blood test results at -10 and 0 weeks (before and after run-in period)
Time Frame
at baseline
Title
HDL-cholestrol
Description
Blood test results following 12 weeks of intervention
Time Frame
12 weeks
Title
CRP
Description
Blood test results on day 0 of High sensitivity C Reactive Protein
Time Frame
at baseline
Title
CRP
Description
Blood test results following 12 weeks of intervention of High sensetivity C reactive protein
Time Frame
12 weeks
Title
Apolipoprotein B100
Description
Blood test results on day 0
Time Frame
at baseline
Title
Apolipoprotein B100
Description
Blood test results follwing 12 weeks of intervention
Time Frame
12 weeks
Title
Apolipoprotein A
Description
Blood test on day 0
Time Frame
at baseline
Title
Apolipoprotein A
Description
Blood test results following 12 weeks of intervention
Time Frame
12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Male or female, >18 years old and ≤ 70 years old, capable and willing to give written informed consent.
Subject must have hyperlipidemia at the screening visit and at the end of the run-in period, defined as: fasting plasma triglycerides > 150 mg/dl and < 500 mg/dl, LDL-cholesterol > 130 mg/dl and < 190 mg/dl.
Fasting plasma glucose (FPG) levels at the screening visit < 110 mg/dl.
Female patient who is of reproductive potential agree to use acceptable methods of birth control
Female patient who is currently receiving hormone replacement therapy continuously 12 weeks before visit 1 (on stable dose) and will agree to do so during the study.
Exclusion Criteria:
Receiving medications or supplements known to affect lipid metabolism.
Uncontrolled hypertension or thyroid disease.
Consume unusual diets - will be determined at the discretion of the investigator.
Gained or lost more than 3 kg during the run-in period.
Patient has history of malignancy ≤ 5 years.
Patients with clinical ischemic CV disease on treatment
Consume 200 grams fish x 2 a week.
Gastrointestinal disease or any disease that the investigator feels would compromise the patient safety or limit his/her successful participation to the study.
Patient has type 1 or type 2 diabetes mellitus.
Patient has uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins
Patient has had active peptic ulcer disease within 3 months of visit 1.
Woman patient is pregnant or breast-feeding or expecting to conceive during the study.
Patient has a history of hypersensitivity or allergy to fish, fish oil, corn oil or soy.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dror Harats, M.D.
Organizational Affiliation
Sheba Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Sheba medical center
City
Tel-HaShomer
ZIP/Postal Code
52621
Country
Israel
12. IPD Sharing Statement
Citations:
PubMed Identifier
20617456
Citation
Bitzur R, Cohen H, Cohen T, Dror TW, Herzog Y, Lifshitz Y, Lubish T, Harats D, Rubinstein A. The metabolic effects of omega-3 plant sterol esters in mixed hyperlipidemic subjects. Cardiovasc Drugs Ther. 2010 Dec;24(5-6):429-37. doi: 10.1007/s10557-010-6249-5.
Results Reference
derived
Learn more about this trial
Effect of Plant Sterols Esterified to Fish Oil Fatty Acids on Plasma Lipid Levels
We'll reach out to this number within 24 hrs